Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced today that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026. The meeting, held on April 23, 2026, included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members. However, the motions on the agenda for the extraordinary part of the meeting were not put to vote, as the required quorum was not reached.
Chris Martin, Chairman of the Board of Directors of Newron, expressed gratitude to shareholders for their trust and welcomed the newly elected Board members, looking forward to their valuable contributions. He also thanked Patrick Langlois and Luca Benatti, who stepped down from the Board after long-standing service, for their support. This leadership change comes as Newron continues to advance its pipeline, particularly its lead compound evenamide, a first-in-class glutamate modulator being developed for treatment-resistant schizophrenia (TRS) and poorly responding patients with schizophrenia.
Newron is a biopharmaceutical company focused on innovative therapies for central and peripheral nervous system diseases. Its lead candidate, evenamide, is currently in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate benefits in TRS and poorly responding patient populations, with significant improvements across key efficacy measures increasing over time, and a favorable safety profile uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea.
Newron’s first marketed product, Xadago®/safinamide, has received marketing authorization for the treatment of Parkinson’s disease in multiple regions, including the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, visit www.newron.com.
The AGM results underscore shareholder support for Newron’s strategic direction as it progresses its CNS pipeline. The election of independent board members with diverse expertise is expected to strengthen governance and oversight. The failure to achieve quorum for extraordinary motions may require future meetings to address those items.
